Last reviewed · How we verify
Fluocinonide Cream 0.1%
Fluocinonide is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Fluocinonide is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, lichen planus, contact dermatitis).
At a glance
| Generic name | Fluocinonide Cream 0.1% |
|---|---|
| Also known as | Vanos |
| Sponsor | Wake Forest University Health Sciences |
| Drug class | Topical corticosteroid (Class III/IV potency) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Fluocinonide works by penetrating the skin and binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators, reduced vasodilation, and suppression of immune cell infiltration. The result is reduced erythema, pruritus, and other signs of cutaneous inflammation.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, lichen planus, contact dermatitis)
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Systemic corticosteroid absorption (with prolonged use or occlusion)
Key clinical trials
- Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma (NA)
- Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis (PHASE2)
- A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis (PHASE4)
- VANOS Cream and Skin Barrier Function (PHASE4)
- Sorafenib-induced Hand- Foot Skin Reaction Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluocinonide Cream 0.1% CI brief — competitive landscape report
- Fluocinonide Cream 0.1% updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI